Sign In

ACS News

Breaking News

HPV Roundtable Emerging Leaders program applications are open

Build your leadership portfolio with the National HPV Vaccination Roundtable.  

The American Cancer Society National HPV Vaccination Roundtable has launched its 2025 Emerging Leaders Program search with newly opened candidate program applications. As this year will be only the second ever cohort of emerging leaders for ACS HPV Vaccination Roundtable, the program is eager to invite another group of early career professionals who are interested in enhancing their leadership skills within HPV vaccination efforts. 

As an opportunity to enlarge your network nationally, engage in new learning possibilities, and shape the future of HPV vaccination best practices and outreach, program participants can expect to connect with national HPV vaccination and public health leaders and enhance their skills, tools, and habits to amplify leadership qualities through the one-year program.   

To further capitalize on learning opportunities, program participants will be offered paid travel to the 2025 ACS HPV Roundtable National Meeting. Fellows represent a diverse group of partners both internal and external to ACS. Employees who engage in HPV vaccination and cancer prevention efforts substantially in their role are encouraged to apply. Applicants should be within a 5- to 10-year period after completion of their last degree or 5 to 10 years since transitioning to the immunization and cancer prevention field.

Applications must be submitted by July 31. Click here to apply. Learn more by checking out the flyer attached below, visiting the website, and watching the 2023 Emerging Leaders Showcase Webinar recording. Any questions may be directed to hpv.vaccination.roundtable@cancer.org


  • July Advocacy Update

    Highlights include Cancer Votes in action, a major milestone for Major Milestone for MCED, and the documentary In Due Season.

    Thanks to all who submitted feedback on this monthly communication last month. We continue to need your thoughts on how we can make the Monthly Advocacy Update as impactful as possible. If you haven’t already, please take a moment to fill out this quick 2-minute survey. Monthly Advocacy Update Feedback 


    A message from ACS CAN President Lisa Lacasse

    Cancer Votes Action

    While these past weeks have brought scorching temperatures to D.C. and around the country, ACS CAN's Cancer Votes program has continued to heat up this election cycle. As a direct result of our team’s advocacy, 34 candidates, including 14 U.S. Senate and 20 U.S. House candidates, have already signed the Cancer Promise. Ahead of the first presidential debate in June, we rallied our online advocates to urge the debate moderators to pose questions centered on health care, resulting in volunteers taking almost 900 online actions. Although our issues weren’t the focus of the debate, we will continue to elevate cancer and health care affordability issues in the 2024 election cycle.

    Next week we are looking forward to a coffee chat with U.S. Senate Candidate Sen. Tammy Baldwin in Wisconsin on July 16, moderated by Phil O'Brien, our Cancer Votes National Ambassador and Board member. We have held other successful coffee chats with candidates, including former Maryland Governor Larry Hogan, a U.S. Senate Candidate and cancer survivor. These chats are key opportunities for our volunteers to pose questions to candidates regarding our cancer priorities. See photo above.

    We currently have 486 Cancer Votes volunteers activated across 46 states and territories. And we are gearing up for our Power to Impact: Essential Briefing for Cancer Votes Volunteers call on July 16 at 7:30 p.m. EST open to all volunteers. I encourage you to follow our Cancer Votes work and share your voice on your social accounts using #CancerVotes and tagging @ACSCAN. 

    Major Milestone for MCED

    June also brought critical progress for our work to advance access to exciting innovation in early detection for Medicare enrollees when the U.S. House Committee on Ways and Means marked up and passed the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act by a vote of 38-0. (See photo at right.) This strong model of bipartisan supported legislation, championed by Representatives Jodey Arrington (R-TX) and Terri Sewell (D-AL), has the backing of 292 members of the House of Representatives and 62 senators, two-thirds of the Congress. In addition to congressional support, more than 520 organizations from across the country, in every state, have signed on to one or more formal letters of support.

    ACS CAN volunteers who flew in from key congressional districts joined the D.C. team for the markup hearing on June 27. ACS CAN was acknowledged as a strong supporter of the bill publicly and repeatedly by members of the Ways and Means Committee during the markup. We posted a video wrap up demonstrating our powerful presence that day. Take a look!

    Join the In Due Season Movement 

    This month I’m excited about special screenings for In Due Season, our new short documentary highlighting how systemic racism contributes to health care policy decisions for Black Americans in the Medicaid coverage gap. Join ACS CAN on Wednesday, July 31, at a special film screening and reception in Washington, D.C. at MLK Jr. Memorial Library. RSVP here. You can also join us August 7 at 7:30 pm for a virtual screening hosted by ACS CAN’s Black Volunteer Caucus in partnership with Black Voters Matter. Register here. Interested in hosting a screening? Please contact, Carter Steger, VP, State and Local Campaigns. 

    Thank you, as always, for your continued commitment to ACS CAN, 


    Judicial Updates

    • The U.S. Supreme Court announced on July 2 that it will hear the Food and Drug Administration’s (FDA) appeal of the e-cigarette case (FDA v. Wages and White Lion Investments dba Triton Distribution) in which the Fifth Circuit vacated marketing denial orders (MDOs) issued by the agency for flavored e-cigarette products. ACS CAN and other public health partners urged the high court to take the case in an amicus brief after the Fifth Circuit decision leaves products like Jimmy the Juice and Strawberry Astronaut on the market. Flavors like these are proven to attract youth and make it harder for adults to quit. Seven other circuit courts have let MDOs issued by FDA stand, so there is a circuit split. ACS CAN plans to continue to engage in the case. 
    • In June, the FDA dealt a blow to public health by authorizing the sale of four menthol e-cigarettes manufactured by NJOY LLC. Before then, the FDA had issued MDOs for every flavored e-cigarette product it has reviewed, previously finding the applicants failed to produce reliable evidence their product benefits public health and had not yet authorized any menthol flavored e-cigarettes. ACS CAN will continue strongly advocating to urge prohibition of all flavors in all tobacco products at all levels of government.  
    • ACS CAN criticized a U.S. Supreme Court decision in a joint statement on Loper Bright Enterprises, as the case undermines federal agencies’ authority to issue and defend regulations. The decision overturned a 40-year-old precedent that required courts to defer to executive agencies when a statute is ambiguous. This could lead to major challenges for the Centers for Medicare and Medicaid Services (CMS) and the FDA. 
    • ACS CAN and 24 other organizations, applauded the U.S. Supreme Court decision in Alliance for Hippocratic Medicine et al. v FDA et al, that allows the drug mifepristone a drug prescribed for the treatment of a variety of life-threatening conditions, including cancer, to remain on the market. The case was thrown out on the grounds that the plaintiffs don’t have standing in their challenge concerning the use and availability of the drug, but ACS CAN remains concerned that other challengers could continue the lawsuit and undercut FDA’s scientific expertise in issuing other drug approvals. 

    Federal Updates

    • The House Appropriations Subcommittee on Labor Health and Human Services considered and approved its draft FY25 appropriations bill that includes increases for federal cancer research funding at the National Cancer Institute (NCI). The House spending bill includes: $48.581 billion for the National Institutes of Health (NIH), which is the same as FY24 funding, which included $7.875 billion for the National Cancer Institute (NCI), an increase of $651.1 million, and $500 million for the Advanced Research Projects Agency for Health (ARPA-H), which is a $1 billion cut from FY24 levels. See our statement. 
    • ACS CAN recently hosted a corporate partner briefing and a Congressional Briefing, Exploring Clinical Trials and Cancer Screenings, with the National Hispanic Medical Association to build support for the Clinical Trail Modernization Act. The recently introduced legislation will ensure that more patients—regardless of their economic means or their geographic location—have a chance to enroll in clinical trials. The briefing featured Congressman Raul Ruiz (D-CA) the lead sponsor of the bill. ACS CAN volunteer and cancer survivor Dulcely Tavarez of New York presented her survivor story along with ACS CAN volunteer Beatrice Cardenas-Duncan of California. The briefing was moderated by ACS CAN’s Director of Federal Relations James Williams and other speakers included Juan Santamaria, MD, FACS, University of Nebraska Medical Center and Estelamari Rodriguez, MD, MPH, University of Miami Health System.
    • ACS CAN was a pivotal sponsor for the National Indian Health Board’s 2024 National Tribal Health Conference and Public Health Summit in Rapid City, SD. Our sponsorship underscored the importance of cancer research, prevention, and treatment for Indian Health. ACS CAN contributed to the conference's content and educational and networking opportunities by hosting a cancer track. Our rich content included a fireside chat, during the opening plenary, and three workshops: Cancer ScreeningMedicaid Unwinding and Protecting Access to Coverage, and Effective Advocacy. We also engaged with the over 1,200 attendees through our exhibit table. ACS CAN and ACS colleagues and ACS CAN volunteers also attended and actively participated in the conference. 

    Take Action

    Urge Congress to increase funding for cancer researchFor the first time ever, there are expected to be more than 2 million cancer diagnoses in the U.S. this year alone. Certain types of cancers are on the rise in younger people. Cancer research is one of our best tools to combat these trends. Join us to advocate for more federal funding for cancer and biomedical research.


    State Updates 

    • Governor Shapiro signed an access to biomarkers bill into law, securing a major win for patients across Pennsylvania. The new law will require all state-regulated health plans, including Medicaid, to cover comprehensive biomarker testing, which will enable more Pennsylvanians to access biomarker testing that can open the door to precision medicine. 
    • The California State legislature passed, and Governor Newsom signed the budget that includes funding to implement biomarker testing beginning this month. 
    • In Ohio lawmakers allocated $50,000 for the Cleveland Hope Lodge in the capital budget to provide structural updates to the American Cancer Society Hope Lodge and the House-passed biomarkers legislation is now headed to the state senate. 

    In Case You Missed It

    • ACS CAN celebrated Juneteenth, which marks the end of slavery in the United States and commemorates the independence of all Black Americans. As part of the lead-up to this important holiday, ACS CAN staff and volunteers across the country participated in Juneteenth events in their local communities. See our recap post on social media. 
    • ACS CAN, along with our volunteer LGBTQIA+ and Allies and Engagement Group, proudly participated in 35 Pride events across 23 states in June with many more planned throughout the year. See our recap post. 
    • ACS CAN hosted the 17th Annual American Cancer Society Cancer Action Network (ACS CAN) Research and Health Equity Breakfast on Tuesday, June 25 in Boston, highlighting the importance of biomarker testing to help end cancer as we know it, for everyone, as well as seizing the opportunity to network with leaders from life sciences, health care, business, policymaking, and American Cancer Society funded cancer researchers. Speakers included ACS and ACS CAN CEO Dr. Karen Knudsen, John F. Crowley, President and CEO of the Biotechnology Innovation Organization, Representative Meghan Kilcoyne, Dr. Naomi Ko, cancer survivor Jung A Han, and ACS CAN Board member and emcee Dana Bernson, MPH.

    Advocacy in the News

    NYTHere’s What the Court’s Chevron Ruling Could Mean in Everyday Terms

    Washington PostWhat the Supreme Court Chevron decision means for environmental rules

    CNNHow the Supreme Court’s blockbuster ‘Chevron’ ruling puts countless regulations in jeopardy

    PBSHow banning medical debt from credit reports could help millions of Americans

    SalonCancer risks are far higher for LGBTQ folks. Here's how health justice groups are fighting back

    Pink SheetSCOTUS' Mifepristone Decision Sets High Bar For US FDA Suits

    Law 3605th Circ. Knocks Out National Block On ACA Preventive Care

    Penn LiveThe Pennsylvania Senate must ensure patients have access to biomarker testing - Opinion

    CBS 6 AlbanyNew paid leave bill fails to pass N.Y. Assembly, advocacy group expresses disappointment

    KTNV Las VegasTwo-time survivor urges screenings for prostate cancer

    Daily MemphianIt’s time for Tennessee to expand Medicaid 



  • Partnership provides free estate planning tools for patients

    The Giving Docs platform provides safe and secure access.

    Traditionally, creating a will can be both time consuming and costly. To solve this, ACS is teaming up with Giving Docs to provide free access to a suite of estate planning essentials. The suite is now available for cancer patients and survivors and includes a guide on creating a free will and a durable power of attorney.

    The tools can be accessed safely and securely on cancer.org or GivingDocs.com/cancer. In addition to a will, patients and survivors can access resources for beneficiary designation – as well as advance healthcare directive. There is no obligation for users to make a charitable contribution when accessing the tools.



  • New study finds most eligible US adults are not getting screened for lung cancer

    ACS researchers stress initiatives to expand access to healthcare and screening facilities to improve early detection and treatment for lung cancer.

    A new study announced June 10, led by American Cancer Society researchers, shows less than one-in-five eligible individuals in the United States were up to date (UTD) with recommended . The screening uptake was much lower in persons without health insurance or usual source of care and in Southern states with the highest lung cancer burden. The findings are published in JAMA (Journal of the American Medical Association) Internal Medicine.

    “Although lung cancer screening rates continue to be considerably low, this research does show an improvement over screening rates reported for previous years,” said Dr. Priti Bandi, scientific director, cancer risk factors and screening surveillance research at ACS. “But we clearly, still have a long way to go. We must push harder to move the needle in the right direction.”

    “Early detection with LCS is critical because lung cancer symptoms often don't appear in the early stages, but when diagnosed and treated early, survival is markedly improved,” added Bandi. “National and state-based initiatives to expand access to healthcare and screening facilities are needed to continue to improve, prevention, early detection and treatment for lung cancer to help save lives.”

    ACS’ advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN), continues to work at all levels of government to advocate for access to lung cancer screenings. “This research further amplifies the critical need for reducing all barriers to access to care to ensure people are able to immediately utilize preventive and early detection screenings at no cost,” said Lisa Lacasse, president of the ACS CAN. “Expanding Medicaid in the 10 states that have yet to do so would significantly improve access to these lifesaving screenings and decrease lung cancer deaths, as well as eliminating patient costs for screening and follow-up tests by all payers, bringing us closer to ending cancer as we know it, for everyone.”

    Other ACS researchers contributing to the study include Jessica StarTyler Kratzer and Dr. Robert SmithDr. Ahmedin Jemal is senior author of the research.

    For information on tobacco cessation, read here

    Several media outlets covered the news, including Newsday.


  • Cost of care discussions rarely documented for patients with advanced cancer

    New study shows this may hinder identifying patient financial needs and tracking outcomes of associated referrals.

    A new large population-based pilot study, announced June 13, led by researchers at the American Cancer Society and the National Cancer Institute shows cost discussions were infrequently documented in medical records of patient diagnosed with advanced non-small cell lung cancer (NSCLC) and melanoma, which may hinder identifying patient financial needs and tracking outcomes of associated referrals. The findings are published in the journal Cancer.

    “Cancer diagnosis and informed treatment decision-making can be complicated, especially when  the costs of care and the potential for patients to experience financial hardship are considered,” said lead study author Dr. Robin Yabroff, scientific vice president, health services research at the ACS. “Professional organizations have long recommended discussions about treatment costs as part of high-quality care, but these discussions continue to be uncommon. We need to do a better job of ensuring that treatment cost discussions between patients and provider teams occur and are well-documented, especially when high-cost treatment options are available.”

    “Efforts to increase cost of care discussions and relevant referrals, as well as their documentation are warranted as part of ongoing quality care improvement,” added Yabroff.

    Like and share the news on X. Also, like and share the ACS News post on X congratulation Dr. Yabroff on becoming a Fellow of ACSO. 


  • ACS, National Cancer Institute, and Cancer Research UK present groundbreaking cancer prevention research conference

    Event is opportunity for researchers across disciplines to engage in, learn about, and discuss the latest concepts.

    The American Cancer Society, the National Cancer Institute, and Cancer Research UK announced that they hosted their first annual conference on cancer prevention research, June 25 – 27, in Boston, MA. The event brings together scientists from discovery biology through translational and behavioral science to population and implementation research to create a thriving multidisciplinary cancer prevention research community. The goal is to help create a “new look” for cancer prevention in the research community, and to showcase research to better understand cancer aetiology, risk factors, intervention development and implementation, and health inequalities in cancer prevention.

    “This is an exciting opportunity for researchers across disciplines to engage in, learn about, and discuss the latest concepts in cancer prevention research,” said Dr. William Dahut, chief scientific officer at ACS. “The conference will be built on a philosophy of using advances in mechanistic understanding to inform more effective ways of preventing cancer.”  

    Like and share CEO Dr. Karen Knudsen’s post on X in which she calls the conference “historic.”


  • New course available for health and fitness professionals

    Partners can receive a discount in July for the ACSM-ACS Cancer Exercise Specialist Course.

    ACS has partnered with the American College of Sports Medicine (ACSM) to develop the ACSM-ACS Cancer Exercise Specialist Course. The course is designed for health care and fitness practitioners looking to provide safe, effective, and individualized exercise programs to anyone living with or beyond a cancer diagnosis. A discount code (ACSPARTNER) is available for the month of July for 20 percent off the price of the course. 

    Research consistently shows that physical activity has benefits for cancer survivors, including during active treatment. The American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors recommend that physical activity assessment and counseling begin as soon as possible after diagnosis, with the goal of helping patients prepare for treatments, tolerate and respond to treatments, and manage some cancer-related symptoms and treatment-related side effects.

    The new ACSM-ACS Cancer Exercise Specialist Course is designed to increase the number of practitioners able to provide advice and deliver safe, effective, and individualized exercise and physical activity programs based on the most current evidence.

    During July, ACS partners (volunteers, health systems, community organizations, etc.) can get 20 percent off the price of the course using the code ACSPARTNER. See the promotional flyer on Brand toolkit for more information and a link to register for the course. 

    The program is appropriate for:

    • Certified fitness professionals, especially those holding ACSM Exercise Physiologist (ACSM-EP®) and Clinical Exercise Physiologist (ACSM-CEP®) certifications.
    • Health professionals, including physical therapists and PT assistants, rehabilitation therapists, nurses and nurse practitioners, physicians and physician assistants who specialize in working with people with cancer.


  • Coaches vs. Cancer Golf Classic receives national attention

    More than 100 golfers raise awareness for ACS mission during two-day event. 

    Recently, Coaches vs. Cancer (CVC) held its annual National Golf Classic at Oak Hill Country Club in Rochester, NY. Described by attendees as one of their favorite ACS events, the two-day classic brought in $793,000 in donations surpassing its initial goal of $700,000, with more donations still coming in.

    The event received national attention on ESPN and welcomed several notable attendees. Sean Farnham, an ACS Board member and ESPN analyst, was in attendance, along with Carlos Boozer, a retired men’s basketball player and ACC Network commentator, who also showed his support by documenting and participating in the annual classic. Alex Myers, Golf Digest senior writer, secured a hole-in-one bringing major attention to the event with a video of this moment shared on SportsCenter.

    The excitement of this weekend was recapped by Golf Digest’s podcast ‘The Loop’ with Sean Farnham and Carlos Boozer inviting more exposure to the event. Locally, Channel 8 News attended and interviewed our very own CEO Dr. Karen Knudsen, as well as Brad Underwood, Illinois head coach and CVC Council chair. A media campaign with Golf Digest for our CVC Experience Auction in November 2023 continues to work toward part of a larger media partnership to help surface conversations about the cancer continuum. 

    In addition to national exposure and an unprecedented amount in donations, the American Cancer Society B. Thomas Golisano Hope Lodge, in Rochester, NY, and the impact of Hope Lodge communities across the US were recognized through a video shown at the event reception, commemorating a cancer survivor’s time at the Rochester lodge and raising another $173,000 in donations. 



  • Decision threatens to disrupt public healthcare system, ACS CAN says

    Organizations disappointed by Supreme Court’s move to eliminate the long-standing rule of Chevron deference.

    On June 28, the Supreme Court of the United States announced its decision on the Loper Bright Enterprises v. Raimondo case and its companion case, Relentless v. Dept. of Commerce. The majority’s opinion abolishes the rule of Chevron deference. ACS, ACS CAN, and our partners are extremely disappointed by the Supreme Court's decision.

    In response to the court’s decision, the following statement was issued by: American Academy of Pediatrics, American Cancer Society, American Cancer Society Cancer Action Network, ALS Association, American Heart Association, American Lung Association, American Public Health Association, American Thoracic Society, Bazelon Center for Mental Health Law, Campaign for Tobacco-Free Kids, Child Neurology Foundation, Epilepsy Foundation, Muscular Dystrophy Association, National Health Law Program, Physicians for Social Responsibility, The Leukemia & Lymphoma Society, and Truth Initiative.

    “As leaders who share a mission to protect and advance the public’s health, our organizations are disappointed by the Supreme Court’s decision today to eliminate the long-standing rule of Chevron deference. As we described in our Amicus Brief, which Justice Kagan drew on in her dissent, this rule has long helped ensure that healthcare laws are interpreted and implemented appropriately. We anticipate that today’s ruling will cause significant disruption to publicly funded health insurance programs, to the stability of this country’s healthcare and food and drug review systems, and to the health and well-being of the patients and consumers we serve.

    “Before today, Chevron deference protected the legal stability of public health programs such as Medicare and Medicaid. It ensured that laws passed by Congress were interpreted and implemented by expert federal agencies such as the Centers for Medicare and Medicaid Services. As our Amicus Brief noted, large health programs such as Medicaid and Medicare, as well as issues related to the Food, Drug and Cosmetic Act, are extremely complex, so it is key that decisions about how to interpret and implement relevant laws are made by experts at government agencies. Yet today’s majority opinion explicitly ends the use of this sensible doctrine.

    “As leading organizations that work on behalf of people across the country who face serious, acute and chronic illnesses, as well as many people who lack access to quality and affordable healthcare, we will continue to work to ensure that healthcare laws are implemented in ways that benefit the public health.”

    The photo above is taken from CEO Dr. Karen Knudsen’s post on X. Like and share it now.


back to top